EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $33.86 Consensus Target Price from Analysts

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has received a consensus recommendation of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have covered the stock in the last year is $33.86.

EYPT has been the subject of several analyst reports. JPMorgan Chase & Co. initiated coverage on shares of EyePoint Pharmaceuticals in a report on Monday, January 22nd. They issued an “overweight” rating and a $35.00 target price for the company. HC Wainwright lowered their target price on shares of EyePoint Pharmaceuticals from $35.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, January 16th. Mizuho raised their target price on shares of EyePoint Pharmaceuticals from $30.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, February 16th. Finally, Capital One Financial restated an “overweight” rating on shares of EyePoint Pharmaceuticals in a report on Friday, February 16th.

Insider Buying and Selling

In related news, insider Dario A. Paggiarino sold 49,325 shares of the firm’s stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $25.66, for a total value of $1,265,679.50. Following the transaction, the insider now owns 36,505 shares of the company’s stock, valued at approximately $936,718.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other EyePoint Pharmaceuticals news, insider Dario A. Paggiarino sold 5,135 shares of the firm’s stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $25.00, for a total transaction of $128,375.00. Following the transaction, the insider now owns 36,505 shares of the company’s stock, valued at approximately $912,625. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Dario A. Paggiarino sold 49,325 shares of the firm’s stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $25.66, for a total transaction of $1,265,679.50. Following the transaction, the insider now directly owns 36,505 shares in the company, valued at approximately $936,718.30. The disclosure for this sale can be found here. Insiders have sold 56,169 shares of company stock valued at $1,437,509 in the last 90 days. Company insiders own 13.05% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Barclays PLC increased its position in EyePoint Pharmaceuticals by 103.4% during the 3rd quarter. Barclays PLC now owns 45,659 shares of the company’s stock valued at $365,000 after purchasing an additional 23,208 shares during the period. TD Asset Management Inc bought a new stake in shares of EyePoint Pharmaceuticals in the 3rd quarter valued at about $574,000. Scotia Capital Inc. boosted its holdings in shares of EyePoint Pharmaceuticals by 144.9% in the 3rd quarter. Scotia Capital Inc. now owns 90,963 shares of the company’s stock valued at $727,000 after buying an additional 53,820 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in shares of EyePoint Pharmaceuticals in the 4th quarter valued at about $820,000. Finally, Jump Financial LLC boosted its holdings in shares of EyePoint Pharmaceuticals by 318.5% in the 3rd quarter. Jump Financial LLC now owns 48,968 shares of the company’s stock valued at $391,000 after buying an additional 37,268 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Trading Down 16.4 %

EYPT stock opened at $17.50 on Friday. EyePoint Pharmaceuticals has a 52 week low of $4.73 and a 52 week high of $30.99. The company has a fifty day simple moving average of $23.91 and a two-hundred day simple moving average of $18.27.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.27. EyePoint Pharmaceuticals had a negative net margin of 153.84% and a negative return on equity of 61.48%. The business had revenue of $14.03 million during the quarter, compared to analyst estimates of $8.71 million. During the same quarter last year, the business earned ($0.61) earnings per share. On average, equities analysts predict that EyePoint Pharmaceuticals will post -1.73 EPS for the current fiscal year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.